Keywords
tumor, diabetic, WDNETs of the GI or thoracic tract
ADVERSE EVENTS, TUMOR

Somatostatin analogs (SSAs) are the mainstay of treatment for patients with advanced, well-differentiated NETs (WDNETs) expressing somatostatin receptors [Between April 2016 and April 2019 we enrolled a total number of 20 patients, whose characteristics are summarized in Additional file Most common treatment-related adverse events (trAEs)The antitumor activity of the experimental treatment is summarized in Additional file Kaplan–Meier curves for progression-free survival (PFS) (Then, we explored the potentially prognostic role of tumor genomic alterations, as evaluated through NGS analysis (Additional file In the whole 24 months follow-up period, we observed no significant changes in any of the metabolic parameters evaluated (Fig. In conclusion, metformin plus lanreotide ATG is safe, well tolerated and active in both non-diabetic and diabetic patients with WDNETs of the GI or thoracic tract. A precocious reduction of HOMA-IR index and plasma cholesterol may predict higher clinical benefit from this treatment. Larger, prospective clinical trials should be conducted to investigate if adding metformin to SSAs results in outcome improvement when compared to SSAs alone in this clinical setting.